Source BioScience Expanding Next-Gen Sequencing Services, Moving into Cancer Dx | GenomeWeb

By Monica Heger

Source BioScience, a UK-based service provider to the healthcare and life science industry, expects its next-gen sequencing services business to edge past its Sanger sequencing business this year, with applications in cancer genomics comprising the majority of its next-gen sequencing-based projects.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.